Analyst firms · Barclays · MRNA
Barclays MRNA price target and rating history
Moderna Inc. (MRNA) · Health Care
Barclays rates Moderna Inc. (MRNA) Equal Weight with a $25 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on MRNA since August 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Barclays's $25 is 56% below that.
- Current rating
- Equal Weight
- Price target
- $25
- Median target, all firms
- $57
- Actions on MRNA
- 4
Barclays price target on MRNA
Every Barclays rating on MRNA
- Jan 28, 2026
- Feb 18, 2025
- Nov 5, 2021
- Aug 6, 2021
How other firms rate MRNA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Mkt Perform | Oct 27, 2026 | |
| Citigroup | Sell | $80 | Sep 30, 2026 |
| Rothschild & Co Redburn | Sell | $81 | Sep 3, 2026 |
| Argus Research | Buy | $180 | Aug 28, 2026 |
| Wolfe Research | Peer Perform | Aug 25, 2026 | |
| BofA Securities | Neutral | Aug 19, 2026 | |
| Barclays | Equal Weight | $25 | Jan 28, 2026 |
| UBS | Neutral | $34 | Jan 7, 2026 |
| Jefferies | Hold | $30 | Dec 12, 2025 |
Questions about Barclays and MRNA
- What is Barclays's price target for MRNA?
- Barclays's latest stated price target for Moderna Inc. (MRNA) is $25, from its action on Jan 28, 2026.
- What is Barclays's rating on MRNA?
- Barclays rates MRNA Equal Weight, a neutral rating, as of Jan 28, 2026.
- When did Barclays last change its view on MRNA?
- On Jan 28, 2026, Barclays resumes coverage at Equal Weight, price target $25.
- How does Barclays's MRNA target compare with other analysts?
- Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Barclays's $25 is 56% below that.
More MRNA rating histories
- William Blair3
- Argus Research3
- Wolfe Research3
- BofA Securities3
- UBS3
- Jefferies5
- HSBC5
- Oppenheimer3
- Deutsche Bank7
- TD Cowen4
- Leerink Partners5
- Morgan Stanley5
- Piper Sandler3
All Barclays ratingsMRNA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.